These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23506303)

  • 21. Evaluating tamsulosin hydrochloride-released microparticles prepared using single-step matrix coating.
    Maeda A; Shinoda T; Ito N; Baba K; Oku N; Mizumoto T
    Int J Pharm; 2011 Apr; 408(1-2):84-90. PubMed ID: 21291970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The development of Eudragit® NM-based controlled-release matrix tablets.
    Dvořáčková K; Kalėdaitė R; Gajdziok J; Rabišková M; Bajerová M; Muselík J; Lažauskas R; Pečiūra R; Bernatonienė J
    Medicina (Kaunas); 2012; 48(4):192-202. PubMed ID: 22836292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methacrylate micro/nano particles prepared by spray drying: a preliminary in vitro/in vivo study.
    Muñoz Ortega B; Sallam MA; Marín Boscá MT
    Drug Deliv; 2016 Sep; 23(7):2439-2444. PubMed ID: 25715809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S; Jeglitsch M; McCloskey E
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.
    Walker AD; Adachi JD
    Curr Med Res Opin; 2011 Sep; 27(9):1749-54. PubMed ID: 21781014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of tablet formulation and hardness on in vitro release of cephalexin from Eudragit L100 based extended release tablets.
    Saravanan M; Nataraj KS; Ganesh KS
    Biol Pharm Bull; 2002 Apr; 25(4):541-5. PubMed ID: 11995942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wurster Fluidised Bed Coating of Microparticles: Towards Scalable Production of Oral Sustained-Release Liquid Medicines for Patients with Swallowing Difficulties.
    Mohylyuk V; Patel K; Scott N; Richardson C; Murnane D; Liu F
    AAPS PharmSciTech; 2019 Nov; 21(1):3. PubMed ID: 31713006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Properties of tableted high-amylose corn starch-pectin blend microparticles intended for controlled delivery of diclofenac sodium.
    Desai KG
    J Biomater Appl; 2007 Jan; 21(3):217-33. PubMed ID: 16443630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel mesalamine-loaded beads in tablets for delayed release of drug to the colon.
    Nguyen C; Christensen JM; Ayres JW
    Pharm Dev Technol; 2012; 17(1):73-83. PubMed ID: 20923254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In brief: delayed-release risedronate (Atelvia).
    Med Lett Drugs Ther; 2011 Mar; 53(1360):24. PubMed ID: 21412209
    [No Abstract]   [Full Text] [Related]  

  • 31. Spray-dried microparticles of glutathione and S-nitrosoglutathione based on Eudragit
    Shah SU; Socha M; Sejil C; Gibaud S
    Ann Pharm Fr; 2017 Mar; 75(2):95-104. PubMed ID: 27770996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats.
    Cruz L; Assumpção E; Andrade SF; Conrado DJ; Kulkamp IC; Guterres SS; Pohlmann AR
    Eur J Pharm Sci; 2010 Aug; 40(5):441-7. PubMed ID: 20471479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained release enteric coated tablets of pantoprazole: formulation, in vitro and in vivo evaluation.
    Wilson B; Babubhai PP; Sajeev MS; Jenita JL; Priyadarshini SR
    Acta Pharm; 2013 Mar; 63(1):131-40. PubMed ID: 23482318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of the direct compression aid Ludiflash(®) for the preparation of pellets via wet extrusion/spheronization.
    Roblegg E; Schrank S; Griesbacher M; Radl S; Zimmer A; Khinast J
    Drug Dev Ind Pharm; 2011 Oct; 37(10):1231-43. PubMed ID: 21438702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formulation, development, and performance evaluation of metoclopramide HCl oro-dispersible sustained release tablet.
    Kasliwal N; Negi JS; Jugran V; Jain R
    Arch Pharm Res; 2011 Oct; 34(10):1691-700. PubMed ID: 22076769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Production of pH-responsive microparticles by spray drying: investigation of experimental parameter effects on morphological and release properties.
    Rizi K; Green RJ; Donaldson M; Williams AC
    J Pharm Sci; 2011 Feb; 100(2):566-79. PubMed ID: 20799364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.
    Sköldenberg OG; Salemyr MO; Bodén HS; Ahl TE; Adolphson PY
    J Bone Joint Surg Am; 2011 Oct; 93(20):1857-64. PubMed ID: 22012522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orodispersible films and tablets with prednisolone microparticles.
    Brniak W; Maślak E; Jachowicz R
    Eur J Pharm Sci; 2015 Jul; 75():81-90. PubMed ID: 25889975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple unit gastroretentive drug delivery systems: a new preparation method for low density microparticles.
    Streubel A; Siepmann J; Bodmeier R
    J Microencapsul; 2003; 20(3):329-47. PubMed ID: 12881114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different modalities of NaCl osmogen in biodegradable microspheres for bone deposition of risedronate sodium by alveolar targeting.
    Nasr M; Awad GA; Mansour S; Taha I; Al Shamy A; Mortada ND
    Eur J Pharm Biopharm; 2011 Nov; 79(3):601-11. PubMed ID: 21827854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.